HCV NS3

By Targets:	HCV (20) HCV Protease (24) Akt (2) Bacterial (1) Dengue virus (1) DNA/RNA Synthesis (3) Flavivirus (1) GLUT (2) Isotope-Labeled Compounds (3) SARS-CoV (13)
By Research Areas:	Cancer (1) Infection (29) Inflammation/Immunology (1) Metabolic Disease (1)

Targets Recommended: HCV HCV Protease

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-I0179

ITMN 4077

HCV Protease Infection

ITMN 4077 is a macrocyclic inhibitor against Hepatitis C Virus (HCV) NS3 protease (EC₅₀: 2131 nM) .

ITMN 4077	HCV Protease	Infection
ITMN 4077 is a macrocyclic inhibitor against Hepatitis C Virus (HCV) NS3 protease (EC₅₀: 2131 nM) .

HY-P2502

Hepatitis Virus C NS3 Protease Inhibitor 2	HCV Protease HCV	Infection
Hepatitis Virus C NS3 Protease Inhibitor 2 is a product-based peptide inhibitor of *hepatitis C virus (HCV) NS3* protease, with a K_i** of 41 nM .

HY-16593

GS-9256

HCV Protease Infection

GS-9256 is a selective HCV NS3 protease inhibitor. GS-9256 has good pharmacokinetic properties and antiviral activity .

GS-9256	HCV Protease	Infection
GS-9256 is a selective **HCV NS3** protease inhibitor. GS-9256 has good pharmacokinetic properties and antiviral activity .

HY-P4035

HCV NS4A Protein (18-40) (JT strain)	HCV	Infection
HCV NS4A Protein (18-40) (JT strain) is an HCV NS4A peptide, which comprised residues 18 to 40 of the NS4A protein and is known to increase the catalytic efficiency of NS3 protease .

HY-10242

Ciluprevir

BILN 2061; BILN 2061ZW
HCV HCV Protease Infection

Ciluprevir(BILN 2061) is a specific and potent peptidomimetic inhibitor of the HCV NS3 protease with an IC₅₀ of 3.0 nM.
HY-18564

HCV-IN-3

HCV Infection

HCV-IN-3 is a hepatitis C virus (HCV) NS3/4a protein inhibitor, with an IC₅₀ of 20 μM, a K_d of 29 μM.
HY-10243

Vaniprevir

MK-7009
HCV HCV Protease Infection

Vaniprevir (MK-7009) is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease.

Ciluprevir BILN 2061; BILN 2061ZW	HCV HCV Protease	Infection
Ciluprevir(BILN 2061) is a specific and potent peptidomimetic inhibitor of the HCV NS3 protease with an IC₅₀ of 3.0 nM.

HCV-IN-3	HCV	Infection
HCV-IN-3 is a hepatitis C virus (HCV) NS3/4a protein inhibitor, with an IC₅₀ of 20 μM, a K_d of 29 μM.

Vaniprevir MK-7009	HCV HCV Protease	Infection
Vaniprevir (MK-7009) is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease.

HY-19840

Voxilaprevir GS-9857	HCV Protease	Infection
Voxilaprevir (GS-9857) is a noncovalent, reversible inhibitor of HCV NS3/4A protease inhibitor (PI) with pangenotypic antiviral activity . Voxilaprevir inhibits genotype 1b and 3a wild-type NS3 proteases with K_i values of 0.038 nM and 0.066 nM, respectively . Voxilaprevir is an orally active direct-acting antiviral agent (DAA) and can be used for HCV infection research .

HY-P4039

Ac-EEVVAC-pNA	HCV Protease	Infection
Ac-EEVVAC-pNA is a chromogenic substrate for a continuous spectrophotometric assay of HCV NS3 protease. The sequence EEVVAC is derived from the 5A-5B cleavage junction of the HCV polyprotein .

HY-N8520

Variculanol	Bacterial	Infection Cancer
Variculanol is an antimicrobial, anticancer and anti-HCV NS3/4A Protease agent which can be extracted from marine fungus Aspergillus versicolor .

HY-10235

Telaprevir Maximum Cited Publications 43 Publications Verification VX-950	HCV Protease HCV SARS-CoV	Infection
Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (K_i) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide . Telaprevir inhibits SARS-CoV-2 3CL ^pro activity .

HY-10235S

Telaprevir-d4 VX-950-d₄	Isotope-Labeled Compounds HCV Protease HCV SARS-CoV	Infection
Telaprevir-d₄ is the deuterium labeled Telaprevir. Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (Ki) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide[1][2][3]. Telaprevir inhibits SARS-CoV-2 3CLpro activity[4].

HY-17634

Glecaprevir 5 Publications Verification ABT-493	HCV HCV Protease SARS-CoV	Infection
Glecaprevir is a novel HCV NS3/4A protease inhibitor, with IC₅₀ values ranging from 3.5 to 11.3 nM. Glecaprevir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 4.09 μM .

HY-N6936

Sennidin A	HCV Akt GLUT	Infection
Sennidin A, isolated from the leaves of Cassia angustifolia, inhibits HCV NS3 helicase, with an IC₅₀ of 0.8 μM. Sennidin A induces phosphorylation of Akt and glucose transporter 4 (GLUT4) translocation. Sennidin A stimulates the glucose incorporation .

HY-126973

BI-1230	HCV Protease	Infection
BI-1230 is potent and digit nanomolar inhibitor of HCV NS3 protease and of viral replication. BI-1230 is also highly selective against other serine/cysteine proteases. BI-1230 shows good Pharmacokinetic(PK) activity .

HY-14434

Asunaprevir 30+ Cited Publications BMS-650032	HCV HCV Protease SARS-CoV	Infection
Asunaprevir (BMS-650032) is a potent and orally bioavailable *hepatitis C virus (HCV) NS3* protease inhibitor, with IC₅₀** of 0.2 nM-3.5 nM . Asunaprevir inhibits SARS-CoV-2 3CL ^pro activity .

HY-10238

Danoprevir 15+ Cited Publications ITMN-191; R7227; RO5190591; RG7227	HCV Protease HCV SARS-CoV	Infection
Danoprevir (ITMN-191) is an orally active NS3/4A protease inhibitor for hepatitis C virus (HCV) with an IC₅₀ of 0.29 nM and is selective for NS3/4A over a panel of 53 proteases (IC₅₀ higher than 10 μM). Danoprevir (ITMN-191) inhibits HCV genotypes 1a, 1b, 4, 5, and 6 (IC₅₀s=0.2-0.4 nM) as well as 2b and 3a (IC₅₀s=1.6, 3.5 nM) . Danoprevir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 0.05 μM .

HY-15256

Faldaprevir BI 201335	HCV Protease	Infection
Faldaprevir (BI 201335) is a potent, orally active and selective noncovalent inhibitor of NS3/4A protease of HCV (hepatitis C virus) genotypes 1a and 1b, with K_i values of 2.6 and 2.0 nM, respectively. Faldaprevir inhibits HCV RNA replication, with EC₅₀ values of 6.5 and 3.1 nM, respectively. Faldaprevir has potent antiviral activity against chronic HCV infection .

HY-N6935

Sennidin B	HCV Akt GLUT	Infection Metabolic Disease
Sennidin B, a stereoisomer isolated from the leaves of Cassia angustifolia, has lower activity than Sennidin A. Sennidin A inhibits HCV NS3 helicase, with an IC₅₀ of 0.8 μM. Sennidin A induces phosphorylation of Akt and glucose transporter 4 (GLUT4) translocation. Sennidin A stimulates the glucose incorporation .

HY-10300

Narlaprevir 4 Publications Verification SCH 900518	HCV HCV Protease SARS-CoV	Infection
Narlaprevir (SCH 900518) is a selective and orally bioavailable NS3 protease inhibitor with a K_i value of 6 nM and an EC₉₀ value of 40 nM . Narlaprevir also inhibits the HCV nonstructural protein 3 serine protease . Narlaprevir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 2.3 μM .

HY-10237

Boceprevir 25+ Cited Publications EBP 520; SCH 503034	HCV Protease HCV SARS-CoV	Infection
Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a K_i of 14 nM in both enzyme assay and an EC₉₀ of 350 nM in cell-based replicon assay . Boceprevir inhibits SARS-CoV-2 3CL ^pro activity .

HY-109571

HZ-1157	Flavivirus Dengue virus HCV Protease	Infection Inflammation/Immunology
HZ-1157 inhibits HCV NS3/4A protease with an IC₅₀ of 1.0 μmol/L. HZ-1157 (4a) has a high dengue virus inhibitory activity (EC₅₀ = 0.15 μM) and is a relatively nontoxic (CC₅₀ > 10 μM) dengue antiviral agent .

HY-P4038

Hepatitis C Virus S5A/5B	HCV Protease	Infection
Hepatitis C Virus S5A/5B is a synthetic peptide substrate. Hepatitis C Virus S5A/5B mimics the NS5A/5B junction of the nonstructural protein (NS), served as the substrate for the study of HCV NS3 protease activity .

HY-10237S

Boceprevir-d9 EBP 520-d₉; SCH 503034-d₉	Isotope-Labeled Compounds HCV Protease HCV SARS-CoV	Infection
Boceprevir-d₉ is the deuterium labeled Boceprevir. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a Ki of 14 nM in both enzyme assay and an EC90 of 350 nM in cell-based replicon assay[1][2][3][4][5]. Boceprevir inhibits SARS-CoV-2 3CLpro activity[6].

HY-10241

Simeprevir 35+ Cited Publications TMC435; TMC435350	HCV HCV Protease SARS-CoV DNA/RNA Synthesis	Infection
Simeprevir (TMC435; TMC435350) is an oral, potent and highly specific *hepatitis C virus (HCV) NS3/4A protease* inhibitor with a K_i of 0.36 nM. Simeprevir inhibits HCV replication with an EC₅₀ of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (M ^pro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .

HY-10241A

Simeprevir sodium TMC435 sodium; TMC435350 sodium	HCV HCV Protease SARS-CoV DNA/RNA Synthesis	Infection
Simeprevir (TMC435; TMC435350) sodium is an oral, potent and highly specific *hepatitis C virus (HCV) NS3/4A protease* inhibitor with a K_i of 0.36 nM. Simeprevir sodium inhibits HCV replication with an EC₅₀ of 7.8 nM. Simeprevir sodium also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir sodium inhibits the main protease (M ^pro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .

HY-10241S

Simeprevir-13C,d3 TMC435-¹³C,d₃; TMC435350-¹³C,d₃	Isotope-Labeled Compounds HCV HCV Protease SARS-CoV DNA/RNA Synthesis	Infection
Simeprevir- ¹³C,d₃ is the ¹³C- and deuterium labeled Simeprevir. Simeprevir is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses[1][2][5].

HY-12594

Paritaprevir 10+ Cited Publications ABT-450; Veruprevir	HCV Protease HCV SARS-CoV	Infection
Paritaprevir (ABT-450) is a potent, orally active and antiviral *non-structural protein 3/4A (NS3/4A) protease* inhibitor with EC₅₀s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.31 μM. Paritaprevir is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor) .

HY-12946A

BI 653048 phosphate
BI 653048 phosphate is a selective and orally active nonsteroidal glucocorticoid (GC) agonist with an IC₅₀ value of 55 nM . BI 653048 phosphate inhibits CP1A2, CYP2D6, CYP2C9, CYP2C19 and CYP3A4 isoforms’ activity and reduces affinity for the hERG ion channel (IC₅₀>30 μM) . BI 653048 phosphate is extracted from patent WO2005028501A1 (Compound 103), is also a HCV NS3 protease inhibitor that can reduce viral loads infected with the hepatitis C virus .

HY-12946

BI 653048
BI 653048 is a selective and orally active nonsteroidal glucocorticoid (GC) agonist with an IC₅₀ value of 55 nM . BI 653048 inhibits CP1A2, CYP2D6, CYP2C9, CYP2C19 and CYP3A4 isoforms’ activity and reduces affinity for the hERG ion channel (IC₅₀>30 μM) . BI 653048 is extracted from patent WO2005028501A1 (Compound 103), is also a HCV NS3 protease inhibitor that can reduce viral loads infected with the hepatitis C virus .

HY-12594A

Paritaprevir dihydrate ABT-450 dihydrate; Veruprevir dihydrate	HCV Protease HCV SARS-CoV	Infection
Paritaprevir (ABT-450) dihydrate is a potent, orally active and antiviral *non-structural protein 3/4A (NS3/4A) protease* inhibitor with EC₅₀s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir dihydrate is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.31 μM. Paritaprevir dihydrate is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir dihydrate can be enhanced by Ritonavir (a CYP450 inhibitor) .

Cat. No.	Product Name

HY-L073

Anti-Hepatitis C Virus Compound Library	283 compounds
Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle. MCE offers a unique collection of 283 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Anti-Hepatitis C Virus Compound Library

283 compounds

Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle.

MCE offers a unique collection of 283 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Cat. No.	Product Name	Type

HY-P4039

Ac-EEVVAC-pNA	Chromogenic Substrates
Ac-EEVVAC-pNA is a chromogenic substrate for a continuous spectrophotometric assay of HCV NS3 protease. The sequence EEVVAC is derived from the 5A-5B cleavage junction of the HCV polyprotein .

Cat. No.	Product Name	Target	Research Area

HY-P5510

Ac-Asp-Glu-Asp(EDANS)-Glu-Glu-Abu-ψ-(COO)Ala-Ser-Lys(DABCYL)-NH2 HCV NS3 protease substrate	Peptides	Others
Ac-Asp-Glu-Asp(EDANS)-Glu-Glu-Abu-ψ-(COO)Ala-Ser-Lys(DABCYL)-NH2 (HCV NS3 protease substrate) is a biological active peptide. (This peptide is a HCV protease substrate incorporating an ester bond between residues P1 and P1. Due to ready transesterification of the scissile bond to the acyl-enzyme intermediate, this substrate shows very high kcat/Km values, enabling detection of activity with subnanomolar nonstructural protein 3 (NS3 protease) concentrations. It is widely used for the continuous assay of NS3 protease activity. Substrate cleavage is proportional to the enzyme concentration with a detection limit for NS3 between 1 nM and 250 pM. Upon cleavage of this substrate, fluorescence can be monitored at Abs/Em = 355/500 nm.)

HY-P2502

Hepatitis Virus C NS3 Protease Inhibitor 2	HCV Protease HCV	Infection
Hepatitis Virus C NS3 Protease Inhibitor 2 is a product-based peptide inhibitor of *hepatitis C virus (HCV) NS3* protease, with a K_i** of 41 nM .

HY-P4035

HCV NS4A Protein (18-40) (JT strain)	HCV	Infection
HCV NS4A Protein (18-40) (JT strain) is an HCV NS4A peptide, which comprised residues 18 to 40 of the NS4A protein and is known to increase the catalytic efficiency of NS3 protease .

HY-P4039

Ac-EEVVAC-pNA	HCV Protease	Infection
Ac-EEVVAC-pNA is a chromogenic substrate for a continuous spectrophotometric assay of HCV NS3 protease. The sequence EEVVAC is derived from the 5A-5B cleavage junction of the HCV polyprotein .

HY-P4038

Hepatitis C Virus S5A/5B	HCV Protease	Infection
Hepatitis C Virus S5A/5B is a synthetic peptide substrate. Hepatitis C Virus S5A/5B mimics the NS5A/5B junction of the nonstructural protein (NS), served as the substrate for the study of HCV NS3 protease activity .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6935

Sennidin B	Infection other families Classification of Application Fields Leguminosae Ketones, Aldehydes, Acids Source classification Phenols Polyphenols Metabolic Disease Plants Cassia angustifolia Disease Research Fields	HCV Akt GLUT
Sennidin B, a stereoisomer isolated from the leaves of Cassia angustifolia, has lower activity than Sennidin A. Sennidin A inhibits HCV NS3 helicase, with an IC₅₀ of 0.8 μM. Sennidin A induces phosphorylation of Akt and glucose transporter 4 (GLUT4) translocation. Sennidin A stimulates the glucose incorporation .

HY-N8520

Variculanol	Structural Classification Microorganisms Terpenoids Sesquiterpenes Source classification	Bacterial
Variculanol is an antimicrobial, anticancer and anti-HCV NS3/4A Protease agent which can be extracted from marine fungus Aspergillus versicolor .

HY-N6936

Sennidin A	Infection other families Classification of Application Fields Ketones, Aldehydes, Acids Source classification Phenols Polyphenols Plants Disease Research Fields	HCV Akt GLUT
Sennidin A, isolated from the leaves of Cassia angustifolia, inhibits HCV NS3 helicase, with an IC₅₀ of 0.8 μM. Sennidin A induces phosphorylation of Akt and glucose transporter 4 (GLUT4) translocation. Sennidin A stimulates the glucose incorporation .

Cat. No.	Compare	Product Name	Species	Source

HY-P74898

	NS3 protease Protein, HCV (GST) Hepatitis C virus (HCV-1a) NS3 protease / helicase immunodominant region Protein ( GST)	Virus	E. coli
	NS3 protease Protein is a zinc-dependent serine protease. NS3 needs to bind to the viral protein NS4A to enable additional conformation changes that enhance activity and appropriate intracellular localization. NS3 protein induces Caspase-8-mediated apoptosis independently of its protease or helicase activity. NS3 protease Protein, HCV (GST) is the recombinant Virus-derived NS3 protease protein, expressed by E. coli , with N-GST labeled tag. The total length of NS3 protease Protein, HCV (GST) is 104 a.a., with molecular weight of ~37.9 kDa.

Cat. No.	Product Name	Chemical Structure

HY-10235S

Telaprevir-d4
Telaprevir-d₄ is the deuterium labeled Telaprevir. Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (Ki) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide[1][2][3]. Telaprevir inhibits SARS-CoV-2 3CLpro activity[4].

HY-10237S

Boceprevir-d9
Boceprevir-d₉ is the deuterium labeled Boceprevir. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a Ki of 14 nM in both enzyme assay and an EC90 of 350 nM in cell-based replicon assay[1][2][3][4][5]. Boceprevir inhibits SARS-CoV-2 3CLpro activity[6].

HY-10241S

Simeprevir-13C,d3

Simeprevir- ¹³C,d₃ is the ¹³C- and deuterium labeled Simeprevir. Simeprevir is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses[1][2][5].


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

HCV NS3

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Natural
Products